Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Trial Profile

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Latanoprost/netarsudil (Primary) ; Latanoprost; Netarsudil
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Mercury 1
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to an Aerie Pharmaceuticals media release, data from this study and Rocket 4 were also included in the Rhopressa™ NDA submission as supportive.
    • 01 Aug 2017 Status changed from active, no longer recruiting to completed, according to an Aerie Pharmaceuticals media release.
    • 19 Jul 2017 Twelve month topline safety results published in an Aerie Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top